Cargando…

A Splice Variant of NCOR2, BQ323636.1, Confers Chemoresistance in Breast Cancer by Altering the Activity of NRF2

Breast cancer is the most common type of female cancer. Reactive oxygen species (ROS) are vital in regulating signaling pathways that control cell survival and cell proliferation. Chemotherapeutic drugs such as anthracyclines induce cell death via ROS induction. Chemoresistance development is associ...

Descripción completa

Detalles Bibliográficos
Autores principales: Leung, Man-Hong, Tsoi, Ho, Gong, Chun, Man, Ellen PS, Zona, Stefania, Yao, Shang, Lam, Eric W.-F., Khoo, Ui-Soon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139508/
https://www.ncbi.nlm.nih.gov/pubmed/32110852
http://dx.doi.org/10.3390/cancers12030533
_version_ 1783518781784457216
author Leung, Man-Hong
Tsoi, Ho
Gong, Chun
Man, Ellen PS
Zona, Stefania
Yao, Shang
Lam, Eric W.-F.
Khoo, Ui-Soon
author_facet Leung, Man-Hong
Tsoi, Ho
Gong, Chun
Man, Ellen PS
Zona, Stefania
Yao, Shang
Lam, Eric W.-F.
Khoo, Ui-Soon
author_sort Leung, Man-Hong
collection PubMed
description Breast cancer is the most common type of female cancer. Reactive oxygen species (ROS) are vital in regulating signaling pathways that control cell survival and cell proliferation. Chemotherapeutic drugs such as anthracyclines induce cell death via ROS induction. Chemoresistance development is associated with adaptive response to oxidative stress. NRF2 is the main regulator of cytoprotective response to oxidative stress. NRF2 can enhance cell growth, antioxidant expression, and chemoresistance by providing growth advantage for malignant cells. Previously, we identified BQ323636.1 (BQ), a novel splice variant of nuclear co-repressor NCOR2, which can robustly predict tamoxifen resistance in primary breast cancer. In this study, we found that BQ was overexpressed in epirubicin-resistant cells and demonstrated that BQ overexpression could reduce the levels of epirubicin-induced ROS and confer epirubicin resistance. In vivo analysis using tissue microarray of primary breast cancer showed direct correlation between BQ expression and chemoresistance. In vitro experiments showed BQ could modulate NRF2 transcriptional activity and upregulate antioxidants. Luciferase reporter assays showed that although NCOR2 repressed the transcriptional activity of NRF2, the presence of BQ reduced this repressive activity. Co-immunoprecipitation confirmed that NCOR2 could bind to NRF2 and that this interaction was compromised by BQ overexpression, leading to increased transcriptional activity in NRF2. Our findings suggest BQ can regulate the NRF2 signaling pathway via interference with NCOR2 suppressive activity and reveals a novel role for BQ as a modulator of chemoresistance in breast cancer.
format Online
Article
Text
id pubmed-7139508
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71395082020-04-10 A Splice Variant of NCOR2, BQ323636.1, Confers Chemoresistance in Breast Cancer by Altering the Activity of NRF2 Leung, Man-Hong Tsoi, Ho Gong, Chun Man, Ellen PS Zona, Stefania Yao, Shang Lam, Eric W.-F. Khoo, Ui-Soon Cancers (Basel) Article Breast cancer is the most common type of female cancer. Reactive oxygen species (ROS) are vital in regulating signaling pathways that control cell survival and cell proliferation. Chemotherapeutic drugs such as anthracyclines induce cell death via ROS induction. Chemoresistance development is associated with adaptive response to oxidative stress. NRF2 is the main regulator of cytoprotective response to oxidative stress. NRF2 can enhance cell growth, antioxidant expression, and chemoresistance by providing growth advantage for malignant cells. Previously, we identified BQ323636.1 (BQ), a novel splice variant of nuclear co-repressor NCOR2, which can robustly predict tamoxifen resistance in primary breast cancer. In this study, we found that BQ was overexpressed in epirubicin-resistant cells and demonstrated that BQ overexpression could reduce the levels of epirubicin-induced ROS and confer epirubicin resistance. In vivo analysis using tissue microarray of primary breast cancer showed direct correlation between BQ expression and chemoresistance. In vitro experiments showed BQ could modulate NRF2 transcriptional activity and upregulate antioxidants. Luciferase reporter assays showed that although NCOR2 repressed the transcriptional activity of NRF2, the presence of BQ reduced this repressive activity. Co-immunoprecipitation confirmed that NCOR2 could bind to NRF2 and that this interaction was compromised by BQ overexpression, leading to increased transcriptional activity in NRF2. Our findings suggest BQ can regulate the NRF2 signaling pathway via interference with NCOR2 suppressive activity and reveals a novel role for BQ as a modulator of chemoresistance in breast cancer. MDPI 2020-02-26 /pmc/articles/PMC7139508/ /pubmed/32110852 http://dx.doi.org/10.3390/cancers12030533 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Leung, Man-Hong
Tsoi, Ho
Gong, Chun
Man, Ellen PS
Zona, Stefania
Yao, Shang
Lam, Eric W.-F.
Khoo, Ui-Soon
A Splice Variant of NCOR2, BQ323636.1, Confers Chemoresistance in Breast Cancer by Altering the Activity of NRF2
title A Splice Variant of NCOR2, BQ323636.1, Confers Chemoresistance in Breast Cancer by Altering the Activity of NRF2
title_full A Splice Variant of NCOR2, BQ323636.1, Confers Chemoresistance in Breast Cancer by Altering the Activity of NRF2
title_fullStr A Splice Variant of NCOR2, BQ323636.1, Confers Chemoresistance in Breast Cancer by Altering the Activity of NRF2
title_full_unstemmed A Splice Variant of NCOR2, BQ323636.1, Confers Chemoresistance in Breast Cancer by Altering the Activity of NRF2
title_short A Splice Variant of NCOR2, BQ323636.1, Confers Chemoresistance in Breast Cancer by Altering the Activity of NRF2
title_sort splice variant of ncor2, bq323636.1, confers chemoresistance in breast cancer by altering the activity of nrf2
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139508/
https://www.ncbi.nlm.nih.gov/pubmed/32110852
http://dx.doi.org/10.3390/cancers12030533
work_keys_str_mv AT leungmanhong asplicevariantofncor2bq3236361conferschemoresistanceinbreastcancerbyalteringtheactivityofnrf2
AT tsoiho asplicevariantofncor2bq3236361conferschemoresistanceinbreastcancerbyalteringtheactivityofnrf2
AT gongchun asplicevariantofncor2bq3236361conferschemoresistanceinbreastcancerbyalteringtheactivityofnrf2
AT manellenps asplicevariantofncor2bq3236361conferschemoresistanceinbreastcancerbyalteringtheactivityofnrf2
AT zonastefania asplicevariantofncor2bq3236361conferschemoresistanceinbreastcancerbyalteringtheactivityofnrf2
AT yaoshang asplicevariantofncor2bq3236361conferschemoresistanceinbreastcancerbyalteringtheactivityofnrf2
AT lamericwf asplicevariantofncor2bq3236361conferschemoresistanceinbreastcancerbyalteringtheactivityofnrf2
AT khoouisoon asplicevariantofncor2bq3236361conferschemoresistanceinbreastcancerbyalteringtheactivityofnrf2
AT leungmanhong splicevariantofncor2bq3236361conferschemoresistanceinbreastcancerbyalteringtheactivityofnrf2
AT tsoiho splicevariantofncor2bq3236361conferschemoresistanceinbreastcancerbyalteringtheactivityofnrf2
AT gongchun splicevariantofncor2bq3236361conferschemoresistanceinbreastcancerbyalteringtheactivityofnrf2
AT manellenps splicevariantofncor2bq3236361conferschemoresistanceinbreastcancerbyalteringtheactivityofnrf2
AT zonastefania splicevariantofncor2bq3236361conferschemoresistanceinbreastcancerbyalteringtheactivityofnrf2
AT yaoshang splicevariantofncor2bq3236361conferschemoresistanceinbreastcancerbyalteringtheactivityofnrf2
AT lamericwf splicevariantofncor2bq3236361conferschemoresistanceinbreastcancerbyalteringtheactivityofnrf2
AT khoouisoon splicevariantofncor2bq3236361conferschemoresistanceinbreastcancerbyalteringtheactivityofnrf2